The topic of this article may not meet Wikipedia's general notability guideline. (November 2025) |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H26N4O4 |
| Molar mass | 446.507 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.